Get the Stockscreener App
56.08
1.59%
0.88
After Hours:
56.08
Biomarin Pharmaceutical Inc stock is traded at $56.08, with a volume of 2.57M.
It is up +1.59% in the last 24 hours and up +5.20% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$55.20
Open:
$55.44
24h Volume:
2.57M
Relative Volume:
0.91
Market Cap:
$10.77B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
20.85
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
-8.53%
1M Performance:
+5.20%
6M Performance:
-3.69%
1Y Performance:
-12.11%
1-Day Range:
$55.20
$56.37
1-Week Range:
$54.36
$61.28
52-Week Range:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
56.08 | 10.60B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.53 | 115.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.14 | 79.76B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
799.33 | 50.16B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
366.86 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.75 | 38.85B | 4.98B | 69.59M | 525.67M | 0.5197 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-06-25 | Downgrade | Stifel | Buy → Hold |
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
4 Value Stocks to Buy As Wall Street Weighs Trump Policies - The Globe and Mail
BioMarin names Arpit Davé as Chief Digital and Information Officer - The American Bazaar
Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now? - Yahoo Finance
BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference - Yahoo Finance
BioMarin Pharmaceutical Reports Preliminary 2025 Revenue, Details Asset Write-Down - marketscreener.com
BioMarin appoints Arpit Davé as chief digital and information officer By Investing.com - Investing.com Nigeria
Lobbying Update: $30,000 of BIOMARIN PHARMACEUTICAL INC. lobbying was just disclosed - Quiver Quantitative
Biomarin Pharmaceutical Inc estimates $3.2 billion in total revenues for FYSEC filing - marketscreener.com
BMRN: Strong growth, pipeline progress, and Amicus integration position for sustained double-digit CAGR - TradingView — Track All Markets
BioMarin Appoints Arpit Davé Chief Digital and Information Officer - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo Finance
Why (BMRN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Veeva and BioMarin form strategic partnership to accelerate therapies By Investing.com - Investing.com Nigeria
How BioMarin Pharmaceutical Inc. (BM8) stock compares with tech leaders2025 EndofYear Setup & AI Powered Buy/Sell Recommendations - ulpravda.ru
Veeva and BioMarin Form Long-Term Strategic Partnership - Sahm
What RSI levels show for BioMarin Pharmaceutical Inc. (BM8) stockPortfolio Performance Summary & High Accuracy Investment Entry Signals - ulpravda.ru
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA - Chartmill
Will BioMarin Pharmaceutical Inc. stock outperform Nasdaq indexIPO Watch & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
What catalysts could drive BioMarin Pharmaceutical Inc. stock higher2025 EndofYear Setup & Fast Exit and Entry Trade Guides - ulpravda.ru
Is BioMarin Pharmaceutical Inc. (BM8) stock a buy during volatile marketsPortfolio Risk Report & Free Community Consensus Stock Picks - ulpravda.ru
Veeva, BioMarin Enter Long-Term Strategic Partnership - Contract Pharma
Veeva Systems Expands Long-Term Partnership With BioMarin Pharmaceutical - Nasdaq
Veeva and BioMarin form strategic partnership to accelerate therapies - Investing.com
BioMarin fends off Kuvan generics competition again - The Pharma Letter
Published on: 2026-01-08 12:48:27 - Улправда
HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver - MSN
10 Magnificent Stocks That Can Make You Richer in 2026 - The Motley Fool
Taking a Fresh Look at BioMarin Pharmaceutical’s (BMRN) Valuation After Its Recent Share Price Rebound - Sahm
How Investors Are Reacting To BioMarin (BMRN) Halting BMN349 And Refocusing Its Rare Disease Pipeline - Yahoo Finance
19,329 Shares in BioMarin Pharmaceutical Inc. $BMRN Acquired by Financiere des Professionnels Fonds d investissement inc. - MarketBeat
Technical Analysis: What RSI levels show for BioMarin Pharmaceutical Inc BM8 stock2025 Market Trends & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Investor Mood: How BioMarin Pharmaceutical Inc stock performs in weak economyJuly 2025 Pullbacks & Safe Entry Trade Reports - moha.gov.vn
Blue Trust Inc. Sells 17,973 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance - FinancialContent
These Bay Area drugmakers are hurtling toward key FDA approval decisions in 2026 - The Business Journals
VIRGINIA RETIREMENT SYSTEMS ET Al Reduces Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
H.C. Wainwright: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Insider Monkey
H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Finviz
12 Best NASDAQ Stocks to Buy in 2026 - Insider Monkey
BioMarin Acquiring Amicus — Both Great Companies, Only One Worth Buying Now (NASDAQ:BMRN) - Seeking Alpha
Is BioMarin Pharmaceutical Inc. (BMRN) the Ridiculously Cheap Stock to Buy Now? - Finviz
Cwm LLC Has $8.90 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
BioCentury’s 2025-26 picks and predictions. Plus: BioMarin and more biotech ICYMI — a BioCentury podcast - BioCentury
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal - FinancialContent
BioMarin ends development of BMN 349 AATD therapy - MSN
BioMarin to Acquire Amicus Therapeutics for $4.8B - Contract Pharma
Rocket Lab, Micron, And CoreWeave Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 22-Dec. 26): Are the Others in Your Portfolio?Astera Labs (NASDAQ:ALAB), BioMarin Pharmaceutical (NASDAQ:BMRN), Ciena (NYSE:CIEN), CoreWeave (NA - Benzinga
Portfolio Update: How BioMarin Pharmaceutical Inc stock performs in weak economy2025 Earnings Impact & Long-Term Investment Growth Plans - moha.gov.vn
Rice Hall James & Associates LLC Boosts Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Pacer Advisors Inc. - MarketBeat
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.44%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):